Content about Staphylococcus aureus

November 7, 2012
FDA issues warning letter to company making illegal claims in support of light therapy device

The Food and Drug Administration on Monday issued a warning letter to The Avalon Effect, a company based in Franklin, Tenn., for its marketing of a light therapy product that claims to cure or treat symptoms of fungal meningitis, methicillin-resistant Staphylococcus aureus, concussions, Lyme disease and other diseases.

SILVER SPRING, Md. — The Food and Drug Administration on Monday issued a warning letter to The Avalon Effect, a company based in Franklin, Tenn., for its marketing of a light therapy product that claims to cure or treat symptoms of fungal meningitis, methicillin-resistant Staphylococcus aureus, concussions, Lyme disease and other diseases.

April 10, 2012
FDA approves Watson diarrhea drug

The Food and Drug Administration has approved a generic version of a drug for diarrhea made by Watson, the company said Tuesday.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic version of a drug for diarrhea made by Watson, the company said Tuesday.

Watson announced the approval of vancomycin hydrochloride capsules in the 125-mg and 250-mg strengths. Vancomycin hydrochloride is used to treat diarrhea associated with Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.

September 14, 2011
Study: Antimicrobial-resistant MRSA revealed; may reverse infection decline

A new resistant strain of methicillin-resistant staphylococcus aureus may be on the rise due to the frequent use of over-the-counter antibacterial ointments, according to a study to be published in the October issue of Emerging Infectious Diseases.

ATLANTA — A new resistant strain of methicillin-resistant staphylococcus aureus may be on the rise due to the frequent use of over-the-counter antibacterial ointments, according to a study to be published in the October issue of Emerging Infectious Diseases.

As reported by CNN.com, Japanese researchers made the finding after testing 259 MRSA strains for susceptibility to bacitracin and neomycin, two of the antibacterial ingredients commonly found in such OTC ointments as Neosporin and Polysporin.

April 22, 2011
Tec Labs to cooperate with FDA over product's MRSA claims

In response to a Food and Drug Administration warning letter, Tec Labs announced on Thursday that the company plans to work with the agency regarding its StaphAseptic first-aid antiseptic and pain-relieving gel.

ALBANY, Ore. — In response to a Food and Drug Administration warning letter, Tec Labs announced on Thursday that the company plans to work with the agency regarding its StaphAseptic first-aid antiseptic and pain-relieving gel.

The FDA on Wednesday issued a total of four warning letters, including the one to Tec Labs, to companies that manufacture and market products claiming to prevent infection from methicillin-resistant Staphylococcus aureus bacteria, or MRSA.

April 21, 2011
FDA warns companies to stop making MRSA claims for over-the-counter products

The Food and Drug Administration on Wednesday issued four warning letters to companies that manufacture and market over-the-counter drug products, including hand sanitizers, that claim to prevent infection from methicillin-resistant Staphylococcus aureus bacteria, or MRSA.

SILVER SPRING, Md. — The Food and Drug Administration on Wednesday issued four warning letters to companies that manufacture and market over-the-counter drug products, including hand sanitizers, that claim to prevent infection from methicillin-resistant Staphylococcus aureus bacteria, or MRSA.

September 16, 2010
Drug-resistant bacterial infections reported in 20 states, worldwide

Drug-resistant bacterial infections recently have been reported in more than 20 states across the United...

September 9, 2010
PhRMA: Drug, vaccine development for infectious diseases grows

Close to 400 drugs and vaccines are in development for fighting infectious diseases, according to...

BOSTON Close to 400 drugs and vaccines are in development for fighting infectious diseases, according to one of the pharmaceutical industry’s largest lobbying groups.

 

The Pharmaceutical Research and Manufacturers of America announced Friday that drug makers have 395 new medicines and vaccines in clinical development or under review by the Food and Drug Administration. These include five vaccines and six drugs for malaria, as well as agents for infections like cholera, methicillin-resistant Staphylococcus aureus and the Ebola virus.